Amanda Eaton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8647874/publications.pdf

Version: 2024-02-01

28 papers	3,165 citations	393982 19 h-index	476904 29 g-index
40 all docs	40 docs citations	40 times ranked	3921 citing authors

#	Article	IF	Citations
1	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2022, 375, 43-50.	6.0	788
2	Homologous and Heterologous Covid-19 Booster Vaccinations. New England Journal of Medicine, 2022, 386, 1046-1057.	13.9	418
3	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. New England Journal of Medicine, 2022, 386, 1088-1091.	13.9	338
4	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2021, , eab3435.	6.0	145
5	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nature Communications, 2017, 8, 15711.	5.8	137
6	Structural diversity of the SARS-CoV-2 Omicron spike. Molecular Cell, 2022, 82, 2050-2068.e6.	4.5	125
7	Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science, 2019, 366, .	6.0	118
8	Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Reports Medicine, 2022, 3, 100679.	3.3	100
9	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. Cell Reports, 2017, 21, 3681-3690.	2.9	97
10	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Science Translational Medicine, 2017, 9, .	5.8	81
11	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nature Communications, 2017, 8, 1732.	5.8	76
12	Cryo-EM structures of SARS-CoV-2 Omicron BA.2 spike. Cell Reports, 2022, 39, 111009.	2.9	74
13	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. Cell Reports, 2017, 18, 2175-2188.	2.9	69
14	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. PLoS Pathogens, 2019, 15, e1008026.	2.1	56
15	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. Npj Vaccines, 2021, 6, 50.	2.9	46
16	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. Cell Reports, 2016, 14, 43-54.	2.9	45
17	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Scientific Reports, 2021, 11, 23921.	1.6	44
18	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. PLoS Pathogens, 2018, 14, e1007431.	2.1	36

#	Article	IF	Citations
19	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. EBioMedicine, 2016, 12, 196-207.	2.7	34
20	mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Reports, 2022, 38, 110514.	2.9	23
21	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. AIDS Research and Human Retroviruses, 2017, 33, 859-868.	0.5	18
22	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. Journal of Virology, 2018, 92, .	1.5	10
23	Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs. Journal of Immunological Methods, 2020, 479, 112736.	0.6	9
24	Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. Human Vaccines and Immunotherapeutics, 2022, 18, 1-10.	1.4	6
25	Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans. PLoS Pathogens, 2019, 15, e1008165.	2.1	5
26	Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. Journal of Virology, 2020, 94, .	1.5	5
27	Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. Frontiers in Immunology, 2021, 12, 670561.	2.2	3
28	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. PLoS Pathogens, 2021, 17, e1009624.	2.1	2